OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Dr. Kumar on Sequencing Selinexor-Based Combinations in Multiple Myeloma

January 8th 2021

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

Dr. Chauhan on Future Directions With Lutathera in GEP-NETs

January 8th 2021

Aman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.

Dr. Mai on Guidelines for Genetic Testing in CRC

January 8th 2021

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

January 8th 2021

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Dr. Braunstein on Management Strategies in Multiple Myeloma

January 7th 2021

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

January 7th 2021

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma

January 7th 2021

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

Dr. Chiorean on the Role of Genetic Testing in Pancreatic Cancer

January 7th 2021

Elena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.

Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer

January 7th 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer

January 7th 2021

Reema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

January 7th 2021

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma

January 7th 2021

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Dr. McGregor on the Focus of Future Research Efforts in RCC

January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer

January 7th 2021

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Dr. Dhir on Modifying Treatment for Adults Versus Pediatric Patients With Epithelioid Sarcoma

January 6th 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

Dr. Bekaii-Saab on Incorporating Mechanisms of Resistance Into Treatment Selection in HCC

January 6th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

January 6th 2021

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Luke on Predictive Versus Prognostic Biomarkers in Melanoma

January 6th 2021

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.